Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays : Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers
American Association for Clinical Chemistry 2022..
The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers provides evidence-based educational documents to facilitate uniform interpretation and utilization of cardiac biomarkers in clinical laboratories and practice. The committee's goals are to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay in clinical practice. Measurement of high-sensitivity cardiac troponin (hs-cTn) assays is a cornerstone in the clinical evaluation of patients with symptoms and/or signs of acute cardiac ischemia. To define myocardial infarction, the Universal Definition of Myocardial Infarction requires patients who manifest with features suggestive of acute myocardial ischemia to have at least one cTn concentration above the sex-specific 99th percentile upper reference limit (URL) for hs-cTn assays and a dynamic pattern of cTn concentrations to fulfill the diagnostic criteria for MI. This special report provides an overview of how hs-cTn 99th percentile URLs should be established, including recommendations about prescreening and the number of individuals required in the reference cohort, how statistical analysis should be conducted, optimal preanalytical and analytical protocols, and analytical/biological interferences or confounds that can affect accurate determination of the 99th percentile URLs. This document also provides guidance and solutions to many of the issues posed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Clinical chemistry - 68(2022), 8 vom: 27. Juli, Seite 1022-1030 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aakre, Kristin M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.07.2022 Date Revised 11.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/clinchem/hvac092 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342373706 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342373706 | ||
| 003 | DE-627 | ||
| 005 | 20231226013950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/clinchem/hvac092 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342373706 | ||
| 035 | |a (NLM)35716089 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aakre, Kristin M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays |b Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.07.2022 | ||
| 500 | |a Date Revised 11.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a American Association for Clinical Chemistry 2022. | ||
| 520 | |a The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers provides evidence-based educational documents to facilitate uniform interpretation and utilization of cardiac biomarkers in clinical laboratories and practice. The committee's goals are to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay in clinical practice. Measurement of high-sensitivity cardiac troponin (hs-cTn) assays is a cornerstone in the clinical evaluation of patients with symptoms and/or signs of acute cardiac ischemia. To define myocardial infarction, the Universal Definition of Myocardial Infarction requires patients who manifest with features suggestive of acute myocardial ischemia to have at least one cTn concentration above the sex-specific 99th percentile upper reference limit (URL) for hs-cTn assays and a dynamic pattern of cTn concentrations to fulfill the diagnostic criteria for MI. This special report provides an overview of how hs-cTn 99th percentile URLs should be established, including recommendations about prescreening and the number of individuals required in the reference cohort, how statistical analysis should be conducted, optimal preanalytical and analytical protocols, and analytical/biological interferences or confounds that can affect accurate determination of the 99th percentile URLs. This document also provides guidance and solutions to many of the issues posed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 99th percentile | |
| 650 | 4 | |a cardiac troponin | |
| 650 | 4 | |a chest pain | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a high-sensitivity cardiac troponin | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 4 | |a myocardial injury | |
| 650 | 4 | |a nonischemic cardiovascular disease | |
| 650 | 4 | |a normality | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a reference interval | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Troponin |2 NLM | |
| 650 | 7 | |a Troponin T |2 NLM | |
| 700 | 1 | |a Saenger, Amy K |e verfasserin |4 aut | |
| 700 | 1 | |a Body, Rick |e verfasserin |4 aut | |
| 700 | 1 | |a Collinson, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Hammarsten, Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Jaffe, Allan S |e verfasserin |4 aut | |
| 700 | 1 | |a Kavsak, Pete |e verfasserin |4 aut | |
| 700 | 1 | |a Omland, Torbjørn |e verfasserin |4 aut | |
| 700 | 1 | |a Ordonez-Lianos, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Apple, Fred S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry |d 1955 |g 68(2022), 8 vom: 27. Juli, Seite 1022-1030 |w (DE-627)NLM000002003 |x 1530-8561 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2022 |g number:8 |g day:27 |g month:07 |g pages:1022-1030 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/clinchem/hvac092 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2022 |e 8 |b 27 |c 07 |h 1022-1030 | ||